1
|
Nasiri K, Mohammadzadehsaliani S, Kheradjoo H, Shabestari AM, Eshaghizadeh P, Pakmehr A, Alsaffar MF, Al-Naqeeb BZT, Yasamineh S, Gholizadeh O. Spotlight on the impact of viral infections on Hematopoietic Stem Cells (HSCs) with a focus on COVID-19 effects. Cell Commun Signal 2023; 21:103. [PMID: 37158893 PMCID: PMC10165295 DOI: 10.1186/s12964-023-01122-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Accepted: 04/05/2023] [Indexed: 05/10/2023] Open
Abstract
Hematopoietic stem cells (HSCs) are known for their significant capability to reconstitute and preserve a functional hematopoietic system in long-term periods after transplantation into conditioned hosts. HSCs are thus crucial cellular targets for the continual repair of inherited hematologic, metabolic, and immunologic disorders. In addition, HSCs can undergo various fates, such as apoptosis, quiescence, migration, differentiation, and self-renewal. Viruses continuously pose a remarkable health risk and request an appropriate, balanced reaction from our immune system, which as well as affects the bone marrow (BM). Therefore, disruption of the hematopoietic system due to viral infection is essential. In addition, patients for whom the risk-to-benefit ratio of HSC transplantation (HSCT) is acceptable have seen an increase in the use of HSCT in recent years. Hematopoietic suppression, BM failure, and HSC exhaustion are all linked to chronic viral infections. Virus infections continue to be a leading cause of morbidity and mortality in HSCT recipients, despite recent advancements in the field. Furthermore, whereas COVID-19 manifests initially as an infection of the respiratory tract, it is now understood to be a systemic illness that significantly impacts the hematological system. Patients with advanced COVID-19 often have thrombocytopenia and blood hypercoagulability. In the era of COVID-19, Hematological manifestations of COVID-19 (i.e., thrombocytopenia and lymphopenia), the immune response, and HSCT may all be affected by the SARS-CoV-2 virus in various ways. Therefore, it is important to determine whether exposure to viral infections may affect HSCs used for HSCT, as this, in turn, may affect engraftment efficiency. In this article, we reviewed the features of HSCs, and the effects of viral infections on HSCs and HSCT, such as SARS-CoV-2, HIV, cytomegalovirus, Epstein-Barr virus, HIV, etc. Video Abstract.
Collapse
Affiliation(s)
- Kamyar Nasiri
- Department of Dentistry, Islamic Azad University, Tehran, Iran
| | | | | | | | - Parisa Eshaghizadeh
- Department of Dental Surgery, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Azin Pakmehr
- Medical Doctor, Tehran University of Medical Science, Tehran, Iran
| | - Marwa Fadhil Alsaffar
- Medical Laboratories Techniques Department / AL-Mustaqbal University College, 51001, Hillah, Babil, Iraq
| | | | - Saman Yasamineh
- Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.
| | - Omid Gholizadeh
- Department of Bacteriology and Virology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
| |
Collapse
|
2
|
Serrano-Aroca Á, Takayama K, Tuñón-Molina A, Seyran M, Hassan SS, Pal Choudhury P, Uversky VN, Lundstrom K, Adadi P, Palù G, Aljabali AAA, Chauhan G, Kandimalla R, Tambuwala MM, Lal A, Abd El-Aziz TM, Sherchan S, Barh D, Redwan EM, Bazan NG, Mishra YK, Uhal BD, Brufsky A. Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era. ACS NANO 2021; 15:8069-8086. [PMID: 33826850 PMCID: PMC8043205 DOI: 10.1021/acsnano.1c00629] [Citation(s) in RCA: 95] [Impact Index Per Article: 31.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Accepted: 04/02/2021] [Indexed: 05/04/2023]
Abstract
Therapeutic options for the highly pathogenic human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the current pandemic coronavirus disease (COVID-19) are urgently needed. COVID-19 is associated with viral pneumonia and acute respiratory distress syndrome causing significant morbidity and mortality. The proposed treatments for COVID-19 have shown little or no effect in the clinic so far. Additionally, bacterial and fungal pathogens contribute to the SARS-CoV-2-mediated pneumonia disease complex. The antibiotic resistance in pneumonia treatment is increasing at an alarming rate. Therefore, carbon-based nanomaterials (CBNs), such as fullerene, carbon dots, graphene, and their derivatives constitute a promising alternative due to their wide-spectrum antimicrobial activity, biocompatibility, biodegradability, and capacity to induce tissue regeneration. Furthermore, the antimicrobial mode of action is mainly physical (e.g., membrane distortion), characterized by a low risk of antimicrobial resistance. In this Review, we evaluated the literature on the antiviral activity and broad-spectrum antimicrobial properties of CBNs. CBNs had antiviral activity against 13 enveloped positive-sense single-stranded RNA viruses, including SARS-CoV-2. CBNs with low or no toxicity to humans are promising therapeutics against the COVID-19 pneumonia complex with other viruses, bacteria, and fungi, including those that are multidrug-resistant.
Collapse
Affiliation(s)
- Ángel Serrano-Aroca
- Biomaterials and Bioengineering Lab, Centro de
Investigación Traslacional San Alberto Magno, Universidad
Católica de Valencia San Vicente Mártir, 46001 Valencia,
Spain
| | - Kazuo Takayama
- Center for iPS Cell Research and Application,
Kyoto University, Kyoto 606-8397,
Japan
| | - Alberto Tuñón-Molina
- Biomaterials and Bioengineering Lab, Centro de
Investigación Traslacional San Alberto Magno, Universidad
Católica de Valencia San Vicente Mártir, 46001 Valencia,
Spain
| | - Murat Seyran
- Doctoral studies in natural and technical sciences (SPL
44), University of Vienna, Währinger Straße, A-1090
Vienna, Austria
| | - Sk. Sarif Hassan
- Department of Mathematics, Pingla Thana
Mahavidyalaya, Maligram, Paschim Medinipur 721140, West Bengal,
India
| | - Pabitra Pal Choudhury
- Applied Statistics Unit, Indian
Statistical Institute, Kolkata 700108, West Bengal,
India
| | - Vladimir N. Uversky
- Department of Molecular Medicine, Morsani College of
Medicine, University of South Florida, Tampa, Florida 33612,
United States
| | | | - Parise Adadi
- Department of Food Science, University of
Otago, Dunedin 9054, New Zealand
| | - Giorgio Palù
- Department of Molecular Medicine,
University of Padova, Via Gabelli 63, 35121 Padova,
Italy
| | - Alaa A. A. Aljabali
- Department of Pharmaceutics and
Pharmaceutical Technology, Yarmouk University-Faculty of
Pharmacy, Irbid 21163, Jordan
| | - Gaurav Chauhan
- School of Engineering and Sciences,
Tecnológico de Monterrey, Av. Eugenio Garza Sada 2501
Sur, 64849 Monterrey, NL, Mexico
| | - Ramesh Kandimalla
- Applied Biology, CSIR-Indian
Institute of Chemical Technology, Uppal Road, Tarnaka, Hyderabad-500007,
India
- Department of Biochemistry,
Kakatiya Medical College, Warangal-506007, Telangana State,
India
| | - Murtaza M. Tambuwala
- School of Pharmacy and Pharmaceutical
Science, Ulster University, Coleraine BT52 1SA, Northern
Ireland, U.K.
| | - Amos Lal
- Department of Medicine, Division of Pulmonary and Critical
Care Medicine, Mayo Clinic, Rochester, Minnesota 55905,
United States
| | - Tarek Mohamed Abd El-Aziz
- Zoology Department, Faculty of Science,
Minia University, El-Minia 61519,
Egypt
- Department of Cellular and Integrative
Physiology, University of Texas Health Science Center at San
Antonio, San Antonio, Texas 78229-3900, United
States
| | - Samendra Sherchan
- Department of Environmental Health Sciences,
School of Public Health and Tropical Medicine, Tulane University of
Louisiana, New Orleans, Louisiana 70112, United
States
| | - Debmalya Barh
- Institute of Integrative
Omics and Applied Biotechnology (IIOAB), Nonakuri, Purba Medinipur,
WB-721172, India
| | - Elrashdy M. Redwan
- Biological Sciences Department,
Faculty of Science, King Abdulaziz University, P.O. Box 80203,
Jeddah 21589, Saudi Arabia
- Therapeutic and Protective Proteins
Laboratory, Protein Research Department, Genetic Engineering and Biotechnology Research
Institute, City for Scientific Research and Technology
Applications, New Borg El-Arab, Alexandria 21934,
Egypt
| | - Nicolas G. Bazan
- Neuroscience Center of Excellence,
School of Medicine, LSU Heath New Orleans, New Orleans,
Louisiana 70112, United States
| | - Yogendra Kumar Mishra
- University of Southern
Denmark, Mads Clausen Institute, NanoSYD, Alsion 2, 6400 Sønderborg,
Denmark
| | - Bruce D. Uhal
- Department of Physiology, Michigan State
University, East Lansing, Michigan 48824, United
States
| | - Adam Brufsky
- University of Pittsburgh
School of Medicine, Department of Medicine, Division of
Hematology/Oncology, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania 15232,
United States
| |
Collapse
|